Market Place
Sourcing Support
Immix Biopharma Advances CAR-T NXC-201 in AL Amyloidosis Trial
02 Oct 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Dr. Comenzo Joins Advisory Board
19 Sep 2024 //
GLOBENEWSWIRE
Immix Biopharma Expands U.S. Sites For AL Amyloidosis Trial NEXICART-2
28 Aug 2024 //
GLOBENEWSWIRE
Immix Biopharma Doses 1st Patient In U.S. AL Amyloidosis Trial
08 Jul 2024 //
GLOBENEWSWIRE
Immix Biopharma to present at Stifel 2024 Cell Therapy Forum
17 Jun 2024 //
GLOBENEWSWIRE
Immix AL Amyloidosis NXC-201 Data At ASGCT Late-Breaking
10 May 2024 //
GLOBENEWSWIRE
Immix EU Orphan Drug Tag for NXC-201 in Multiple Myeloma
29 Apr 2024 //
GLOBENEWSWIRE
Immix Biopharma on Track to Dose NXC-201 Patients in United States
18 Apr 2024 //
GLOBENEWSWIRE
Immix: NXC-201 Data For ASGCT Oral Presentation
15 Apr 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Major Comp Cancer Center as Lead Site for NXC-201 AL
20 Mar 2024 //
GLOBENEWSWIRE
Immix Bio Announces œBe Proactive in AL AL Amyloidosis Awareness Initiative
05 Mar 2024 //
GLOBENEWSWIRE
Immix Biopharma 12 Month Review Progress Update
21 Feb 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Closing of $15 Million Public Offering of Common Stock
08 Feb 2024 //
GLOBENEWSWIRE
Immix Biopharma Awarded European Union Orphan Drug Designation for NXC-201
07 Feb 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Proposed Public Offering of Common Stock
05 Feb 2024 //
GLOBENEWSWIRE
Immix Biopharma Announces Pricing of $15 Million Public Offering of Common Stock
05 Feb 2024 //
GLOBENEWSWIRE
Immix Statement On Labeling Change Notification For Approved CAR-T Products
24 Jan 2024 //
GLOBENEWSWIRE
Nexcella Announces Dr. Vaishali Sanchorawala Joins Scientific Advisory Board
04 Jan 2024 //
GLOBENEWSWIRE
Nexcella Announces Dr. Marko Radic Joins Scientific Advisory Board
18 Dec 2023 //
GLOBENEWSWIRE
Immix Biopharma Announces 100% Overall Response Rate for CAR-T NXC-201
11 Dec 2023 //
PRESS RELEASE
Immix to Present at the 2023 JMP Securities Hematology and Oncology Summit
30 Nov 2023 //
GLOBENEWSWIRE
Immix Biopharma to Host KOL Event to Discuss its BCMA
22 Nov 2023 //
GLOBENEWSWIRE
Immix Biopharma Announces FDA Approval of IND Application for CAR-T NXC-201
21 Nov 2023 //
GLOBENEWSWIRE
Immix Biopharma Presents NXC-201 Data at 65th ASH
06 Nov 2023 //
GLOBENEWSWIRE
Immix Announces NXC-201 AL Amyloidosis Clinical Data Accepted for Presentation
16 Aug 2023 //
GLOBENEWSWIRE
Nexcella Announces NXC-201 Multiple Myeloma Data Accepted for Presentation
25 Jul 2023 //
GLOBENEWSWIRE
Immix Bio Reports 2nd Positive Trial Data Readout in IMX-110 IMMINENT-01 Trial
17 Jul 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Edward J. Borkowski, former CFO
22 Jun 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Jeffrey H. Cooper, BOD
20 Jun 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella Appoints Mary Sue Coleman, formerJ&J BOD
16 Jun 2023 //
GLOBENEWSWIRE
Immix Biopharma Completes $5 Million At-The-Market Equity Offering Program
14 Jun 2023 //
GLOBENEWSWIRE
Nexcella Appoints Henry McKinnell, Jr., former Chairman & CEO of Pfizer Inc
12 Jun 2023 //
GLOBENEWSWIRE
Nexcella Announces Commencement of NXC-201 Engineering Batches at Site
26 May 2023 //
GLOBENEWSWIRE
Immix Biopharma Announces Positive NXC-201 Clinical Results at ASGCT
21 May 2023 //
GLOBENEWSWIRE
Immix Biopharma Announces Late-Breaking NXC-201 Clinical Data Abstract
04 May 2023 //
GLOBENEWSWIRE
Immix reports positive interim results from cancer combo therapy trial
04 May 2023 //
CLINICAL TRIALS ARENA
Immix Biopharma Announces Early Positive IMX-110 Interim Clinical Trial Data
03 May 2023 //
GLOBENEWSWIRE
Nexcella & Immix Biopharma subsidiary, Positive 58-Patient NXC-201 Clinical Data
26 Apr 2023 //
GLOBENEWSWIRE
Nexcella, an Immix Biopharma Subsidiary, Announces 2023 NXC-201 Efficacy
31 Mar 2023 //
GLOBENEWSWIRE
Nexcella, an Immix Subsidiary, Announces New Positive NXC-201 Clinical Data
23 Mar 2023 //
GLOBENEWSWIRE
Immix Biopharma Confirms No Exposure to Silicon Valley Bank or Silvergate Bank
10 Mar 2023 //
GLOBENEWSWIRE
ImmixBio to Discuss Recent Positive NXC-201 Clinical Data in AL Amyloidosis
06 Mar 2023 //
GLOBENEWSWIRE
Immix Biopharma Announces Dosing of First 2 Patients in its IMX-110
07 Feb 2023 //
GLOBENEWSWIRE
Immix Biopharma Doses Additional Patients in Ongoing Phase 1b/2a IMX-110 Trial
13 Jan 2023 //
GLOBENEWSWIRE
Immix Biopharma Subsidiary Nexcella, Inc. Announces Additional Positive NXC-201
06 Jan 2023 //
GLOBENEWSWIRE
Hadassah Medical and Bar-Ilan University Collaborate with Immix BioPharma
04 Jan 2023 //
PR NEWSWIRE
Immix Biopharma Files $250 Million Mixed Shelf; Shares up After Hours
03 Jan 2023 //
FIRST WORLD PHARMA
Immix Biopharma Announces 16th Patient Dosing in Ongoing Phase 1b/2a IMX-110
20 Dec 2022 //
GLOBENEWSWIRE
ImmixBio Ships Tislelizumab for Patient Dosing in its Combination Trial
19 Dec 2022 //
GLOBENEWSWIRE
Immix Biopharma in-licenses NXC-201 Demonstrating High Response Rate
14 Dec 2022 //
GLOBENEWSWIRE
Immix Announces Patient Dosing in Ongoing Phase 1b/2a IMX-110 Monotherapy Trial
13 Dec 2022 //
GLOBENEWSWIRE
ImmixBio Releases and Ships Scaled-Up GMP Batches of IMX-110 for Clinical Trial
12 Dec 2022 //
GLOBENEWSWIRE
Immix Biopharma Receives Institutional Review Board Approval to IMX-110
11 Nov 2022 //
GLOBENEWSWIRE
Immix to Present Milestones Achieved to Enable Kick-Off of 2 IMX-110 Trials
25 Oct 2022 //
GLOBENEWSWIRE
Immix Biopharma Announces Share Repurchase Program
09 May 2022 //
GLOBENEWSWIRE
Immix Biopharma, Inc. says IMMX Milestone Day to be Held on April 5, 2022
07 Mar 2022 //
GLOBENEWSWIRE
ImmixBio Initiates IMX-110 GMP Manufacturing Scale-Up
31 Jan 2022 //
GLOBENEWSWIRE
ImmixBio Shows Positive IMX-110 Phase 1b/2a Interim Clinical Trial Safety Data
19 Jan 2022 //
GLOBENEWSWIRE
ImmixBio IMX-110 Produced 50% Positive Response Rate in First-Line-Therapy
12 Jan 2022 //
GLOBENEWSWIRE
